Penserra Capital Management LLC bought a new stake in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 44,180 shares of the company's stock, valued at approximately $1,986,000. Penserra Capital Management LLC owned approximately 0.12% of Harrow as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in HROW. Charles Schwab Investment Management Inc. lifted its holdings in shares of Harrow by 195.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company's stock valued at $11,313,000 after buying an additional 166,602 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Harrow in the third quarter valued at approximately $460,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Harrow in the 3rd quarter worth $5,864,000. First Turn Management LLC acquired a new position in Harrow in the 3rd quarter valued at approximately $14,683,000. Finally, Quest Partners LLC bought a new position in Harrow in the third quarter worth $29,000. Institutional investors and hedge funds own 72.76% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on the stock. Craig Hallum increased their target price on shares of Harrow from $45.00 to $65.00 and gave the stock a "buy" rating in a research report on Friday, October 4th. B. Riley reaffirmed a "buy" rating and set a $50.00 price target on shares of Harrow in a research report on Thursday, August 29th. Finally, Lake Street Capital increased their target price on shares of Harrow from $45.00 to $55.00 and gave the stock a "buy" rating in a report on Friday, October 4th.
Get Our Latest Stock Analysis on Harrow
Harrow Price Performance
NASDAQ:HROW traded up $0.18 during mid-day trading on Tuesday, reaching $42.24. The stock had a trading volume of 254,890 shares, compared to its average volume of 512,685. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow, Inc. has a 12 month low of $8.72 and a 12 month high of $59.23. The stock has a market capitalization of $1.50 billion, a PE ratio of -44.30 and a beta of 0.76. The stock has a 50-day simple moving average of $47.84 and a two-hundred day simple moving average of $33.89.
Harrow Profile
(
Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Further Reading
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
